ethyl (3-acetamidophenoxy)acetate | 93136-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (3-acetamidophenoxy)acetate
• 英文别名: (3-acetylamino-phenoxy)-acetic acid ethyl ester；ethyl 2-(3-acetamidophenoxy)acetate
• CAS: 93136-35-7
• 化学式: C₁₂H₁₅NO₄
• mdl: MFCD11174629
• 分子量: 237.255
• InChiKey: GXUBKRJMXZPTFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  411.2±25.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (3-acetamidophenoxy)acetate 在 一水合肼 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 异丙醇 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Nimavat; Mohan; Saravanan, Asian Journal of Chemistry, 2013, vol. 25, # 3, p. 1691 - 1694

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基苯酚 在 potassium carbonate 作用下， 以 溶剂黄146 、 丙酮 为溶剂， 反应 28.0h， 生成 ethyl (3-acetamidophenoxy)acetate
  参考文献：
  名称：

  Nimavat; Mohan; Saravanan, Asian Journal of Chemistry, 2013, vol. 25, # 3, p. 1691 - 1694

  摘要：

  DOI：

文献信息

• [EN] EP2 RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS EP2
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005080367A1

  公开（公告）日：2005-09-01

  A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).

  一个由化学式（I）或其盐、溶剂合物和化学保护形式组成的化合物，其中：R5是一个可选择取代的C5-20芳基或C4-20烷基基团；A选自由化合物（Ai）、（Aii）、（Aiii）组成的群；D选自由化合物（Di）、（Dii）、（Diii）、（Div）、（Dv）组成的群；B选自由化合物（Bi）、（Bii）、（Biii）、（Biv）、（Bv）组成的群。
• EP2 receptor agonists
  申请人：Oxford William Alexander

  公开号：US20050256170A1

  公开（公告）日：2005-11-17

  A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R 3 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 4 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 6 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where R N′ is selected from H and C 1-4 alkyl; where one of R P3 and R P4 is —C m alkylene-R 2 and the other of R P3 and R P4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when R P3 is —C m alkylene-R 2 , m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R 2 is tetrazol-5-yl, m+n may be 0; or where one of R P3 and R P4 is —O—CH 2 —R 2 , and the other of R P3 and R P4 is H, n is 0; R N is H or optionally substituted C 1-4 alkyl; R 2 is either: —CO 2 H (carboxy); —CONH 2 ; —CH 2 -OH; or tetrazol-5-yl.

  化合物的化学式(I)：或其盐，溶剂合物和化学保护形式，其中：R5是可选择的取代的C5-20芳基或C4-20烷基基团；A选自以下组：其中X和Y选自O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；以及N和O，其中虚线表示适当位置的双键，Q为N或CH；R3选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；R4选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；R6选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；D选自：B选自以下组：其中RN'选自H和C1-4烷基；其中RP3和RP4中的一个是—Cm烷基-R2，另一个是H，m和n可以为0或1，m+n=1或2；当RP3是—Cm烷基-R2时，m也可以为2或3，m+n=1、2、3或4，当R2为四唑-5-基时，m+n可以为0；或其中RP3和RP4中的一个是—O—CH2—R2，另一个是H，n为0；RN为H或可选择的取代的C1-4烷基；R2为以下之一：—CO2H（羧基）；—CONH2；—CH2-OH；或四唑-5-基。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。
• EP2 RECEPTOR AGONISTS
  申请人：Oxford Alexander William

  公开号：US20080119526A1

  公开（公告）日：2008-05-22

  A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R 3 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 4 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 6 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where R N′ is selected from H and C 1-4 alkyl; where one of R P3 and R P4 is —C m alkylene-R 2 and the other of R P3 and R P4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when R P3 is —C m alkylene-R 2 , m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R 2 is tetrazol-5-yl, m+n may be 0; or where one of R P3 and R P4 is —O—CH 2 —R 2 , and the other of R P3 and R P4 is H, n is 0; R N is H or optionally substituted C 1-4 alkyl; R 2 is either: —CO 2 H (carboxy); —CONH 2 ; —CH 2 —OH; or tetrazol-5-yl.

  化合物的化学式（I）：或其盐，溶剂合物和化学保护形式，其中：R5是可选取代的C5-20芳基或C4-20烷基基团；A选自以下组：其中X和Y选自以下组：O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；以及N和O，其中虚线表示适当位置的双键，Q为N或CH；R3选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；R4选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；R6选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；D选自：B选自以下组：其中RN'选自H和C1-4烷基；其中RP3和RP4之一为—Cm烷基-R2，另一个为H，m和n可以为0或1，m+n=1或2；当RP3为—Cm烷基-R2时，m也可以为2或3，m+n=1，2，3或4，当R2为四唑-5-基时，m+n可以为0；或其中RP3和RP4之一为—O—CH2—R2，另一个为H，n为0；RN为H或可选取代的C1-4烷基；R2为：—CO2H（羧基）；—CONH2；—CH2—OH；或四唑-5-基。
• EP2 Receptor Agonists
  申请人：Oxford Alexander William

  公开号：US20100261760A1

  公开（公告）日：2010-10-14

  The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.

  本公开提供EP2受体激动剂化合物以及使用这些化合物来治疗可以通过EP2受体激动治疗缓解的疾病的方法。